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Caspases are molecules involved in the terminal execution of
apoptosis (Thornberry et al, 1994; Alnemri et al, 1996; Barge et al,
1997; Harvey et al, 1997; Thornberry and Lazebnik, 1998). They
are activated in a cascade-like fashion and are able to cleave
substrate proteins at a consensus sequence following aspartic acid
residues which may, however, be different for different caspases
(Patel et al, 1996; Faleiro et al, 1997; Thornberry and Lazebnik,
1998). Their substrates include DNA repair enzymes, such as
poly(ADP-ribose)polymerase, several structural proteins of the
cells, such as nuclear lamins, fodrin, b-catenin and cytokeratin 18,
oncoproteins such as mdm2 and tumour suppressor gene products
such as retinoblastoma protein (Patel et al, 1996; Rao et al, 1996;
Brancolini et al, 1997; Caulin et al, 1997; Chen et al, 1997; Tan et
al, 1997). Caspases are also able to activate DNAase and are thus
required for the typical DNA fragmentation found in apoptosis
(Enari et al, 1998; Janicke et al, 1998). They are resident proteins
of the cytosol and when activated, the aminoterminal fragment of
the molecule is removed and the rest of the molecule is cleaved
into 10- and 20-kDa fragments, which form an active a2b2
tetrameric structure (Thornberry et al, 1994; Martins et al, 1997;
Thornberry and Lazebnik, 1998).
There are at least 13 mammalian caspases known so far
(Thornberry and Lazebnik, 1998). They can be divided in
subgroups according to their phylogenetic development, structure
or their order in the caspase activation cascade (Alnemri et al,
1996; Barge et al, 1997; Harvey et al, 1997). Caspases can be acti-
vated by mitochondrial substances such as cytochrome c or apop-
tosis-inducing factor (AIF) the release of which is induced by
changes in the mitochondrial membrane permeability or electric
potential (Liu et al, 1996; Kluck et al, 1997; Manon et al, 1997;
Yang et al, 1997). Release of cytochrome c, for instance, first
leads to activation of caspase 9 which then activates caspase 3
(Nijhawan et al, 1997). The changes in the mitochondrial
membranes is influenced by members of the bcl-2 family proteins
(Kluck et al, 1997; Manon et al, 1997; Yang et al, 1997). These
proteins modulate the apoptotic response and they can be either
pro- or antiapoptotic (Yang and Korsmeyer, 1996; Kroemer,
1997). Their structure is reminiscent of membrane pore forming
proteins, such as cholera toxins, and bcl-xL and bcl-2 have been
shown to inhibit release of cytochrome c or AIF from mitochon-
dria while bax has been shown to promote it (Kluck et al, 1997;
Manon et al, 1997; Minn et al, 1997; Yang et al, 1997).
The caspase cascade can also be activated directly through activa-
tion of the tumour necrosis factor (TNF) receptors such as APO-
1/FAS/CD95. The APO-1/FAS/CD95 receptor is stimulated by
binding of the FAS ligand (Fraser and Evan, 1996; Nagata, 1997).
Upon attachment with the FAS ligand the APO-1/FAS/CD95
receptor oligomerizes, and FADD/MORT1 and FLICE (procaspase
8) become associated with it, forming the so-called death-inducing
signal complex (DISC) (Muzio et al, 1996; Nagata, 1997). This is
followed by activation of procaspase 8, which leads to the activation
of other downstream caspases and to an apoptotic demise of the cell
(Muzio et al, 1996; Nagata, 1997).
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Summary The aim of this investigation was to study the expression of caspases 3, 6 and 8 and their association to apoptosis in preneoplastic
and neoplastic lesions of the breast. The material consisted of nine benign breast epithelial hyperplasias, 15 atypical hyperplasias, 74 in situ
and 82 invasive carcinomas. The extent of apoptosis was assessed by the TUNEL method and caspase 3, 6 and 8 expression by
immunohistochemistry with specific antibodies. Increased caspase 3 immunopositivity, as compared to staining of normal breast ductal
epithelium, was seen in 22% of benign epithelial hyperplasias, 25% of atypical hyperplasias, 58% of in situ carcinomas and 90% of invasive
carcinomas. The corresponding percentages for caspase 6 and 8 were 11%, 25%, 60%, 87% and 22%, 57%, 84%, 83% respectively. In high-
grade in situ lesions there were significantly more cases with strong caspase 3, 6 and 8 immunoreactivity than in low- and intermediate-grade
lesions (P = 0.0045, P = 0.049 and P = 0.0001 respectively). In invasive carcinomas, however, no association between a high tumour grade
and caspase 3, 6 or 8 expression was found (P = 0.27, P = 0.26 and P = 0.69 respectively). The mean apoptotic index was 0.14 ± 0.14% in
benign epithelial hyperplasias, 0.17 ± 0.12% in atypical hyperplasias, 0.61 ± 0.88% in in situ carcinomas and 0.94 ± 1.21% in invasive
carcinomas. In all cases strong caspase 3, 6 and 8 positivity was significantly associated with the extent of apoptosis (P < 0.001, P = 0.015
and P = 0.050 respectively). The results show that synthesis of caspases 3, 6 and 8 is up-regulated in neoplastic breast epithelial cells in
parallel to the increase in the apoptotic index and progression of the breast lesions. © 1999 Cancer Research Campaign
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Several studies have shown that apoptosis is increased in malig-
nant tumors (reviewed in Soini et al, 1998). In breast carcinomas,
high-grade lesions display a higher apoptotic index than low-grade
lesions (Lipponen et al, 1994). Apoptosis in breast carcinoma is
also associated with other parameters, such as proliferation,
tumour ploidy and survival and it is inversely associated with a
positive oestrogen or progesterone receptor status and bcl-2
expression (Lipponen et al, 1994; Mustonen et al, 1997). The anti-
apoptotic effect of a positive oestrogen receptor status is mediated
through stimulation of bcl-2 mRNA synthesis by oestrogen (Wang
and Phang, 1995). Decreased expression of pro-apoptotic bax is
associated with a poor prognosis of the breast carcinoma patients
due to development of resistance to chemotherapeutic agents
(Wang and Phang, 1995).
The immunohistochemical expression and distribution of
different caspases and their relation to apoptosis in breast carci-
nomas and preneoplastic lesions has not previously been studied.
In this study we evaluated the immunohistochemical distribution
of caspases 3, 6 and 8 in preneoplastic and neoplastic lesions of the
breast and their relation to the apoptotic index, as determined by
the TUNEL method. These three caspases were chosen because of




One hundred and eighty breast lesions consisting of 82 invasive
carcinomas, 74 in situ carcinomas, 15 atypical hyperplasias and
nine benign epithelial hyperplasias were collected from the files of
the Department of Pathology, Oulu University Hospital. All mate-
rial was fixed in 10% neutral formalin and embedded in paraffin.
The invasive carcinomas consisted of 71 ductal, seven lobular, two
mucinous, one apocrine and one tubular carcinoma. The in situ
carcinomas consisted of 26 cribriform, 18 comedo, 11 solid, seven
papillary and 12 lobular in situ lesions. The 15 atypical hyper-
plasias consisted of 13 ductal and two lobular hyperplasias. The
diagnosis was based on the AFIP classification of breast tumours
(Rosen and Oberman, 1992). The grades of the ductal carcinomas
were evaluated according to the criteria of Bloom and Richardson,
and the grades of the in situ lesions according to the criteria of
Holland et al (Holland et al, 1990; Elston and Ellis, 1991). The
atypical hyperplasias were defined according to Tavassoli (1992).
First, the apoptotic index was determined from all these tumours.
Caspase 3, 6 and 8 immunohistochemistry was performed from
tumour blocks where representative areas of the breast lesions were
still available after the apoptotic labelling had been performed. The
number of these cases is shown in Table 1. The mean follow-up
was 5.7 ± 2.9 years. There were 20 stage I, 21 stage II, 21 stage III
and 11 stage IV tumours. Anti-oestrogenic treatment was given to
40 patients, 35 patients received cytostatic treatment and 30 radia-
tion therapy in some stage of the disease.
Immunohistochemical stainings
Polyclonal rabbit anti-human caspase-3 antibody was purchased
from Pharmingen (San Diego, CA, USA). According to the manu-
facturer, the antibody recognizes both the unprocessed 32 kDa
pro-caspase-3 molecule and the fragmented larger active 17 kDa
unit. Polyclonal goat anti-human antibodies to caspase 6 (mch2)
and caspase 8 (mch5) were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). According to the
manufacturer, the mch2 antibody recognizes amino acids 157–176
and mch5 amino acids 354–373 of the carboxy terminal part of the
proteins, which both belong to the processed p20 fragment of the
protein. The two antibodies thus recognize both the unprocessed
and the cleaved or activated form of both caspases.
Before application of the primary antibodies, the sections were
heated in a microwave oven in 10 mM citric acid monohydrate,
pH 6.0, for 5–10 min. After a 60-min incubation with the primary
antibody (dilution 1:500 for anti-caspase 3, 1:100 for anti-caspase
6 and 8), a biotinylated secondary anti-rabbit or anti-goat antibody
(all three from Dakopatts, Copenhagen, Denmark) was applied
(dilution 1:200–300) followed by the avidin–biotin–peroxidase
complex (Dakopatts).
For all immunostainings, the colour was developed by
diaminobenzidine, whereafter the sections were lightly counter-
stained with methyl green and mounted with Eukitt (Kindler,
Freiburg, Germany).
Table 1 The extent of apoptosis and caspase 3, 6 and 8 immunoreactivity in hyperplasias, atypical hyperplasias, in-situ and invasive carcinomas of the breast
Diagnosis Apoptosis % Caspase 3 Caspase 6 Caspase 8
+ ++ +++ + ++ +++ + ++ +++
Hyperplasia 0.14 ± 0.14 7 2 0 8 1 0 7 2 0
Atypical hyperplasia 0.17 ± 0.12 9 2 1 9 3 0 6 8 0
In-situ carcinoma 0.61 ± 0.88 27 21 16 27 29 12 11 40 18
Comedo 1.09 ± 1.28 5 3 9 6 5 7 1 7 10
Solid 0.79 ± 0.81 3 6 0 4 6 0 0 8 2
Cribriform 0.52 ± 0.76 10 3 7 11 8 5 6 15 2
Papillary 0.17 ± 0.12 5 1 0 2 3 0 2 3 1
Lobular 0.20 ± 0.10 4 8 0 4 7 0 2 7 3
Invasive carcinoma 0.94 ± 1.21 7 14 49 9 35 27 11 27 30
Ductal 1.00 ± 1.26 4 13 44 8 31 23 10 23 26
Lobular 0.54 ± 0.60 2 1 4 1 3 3 1 3 3
Mucinous 0.47 ± 0.79 1 0 1 0 1 1 0 1 1
+ = negative or weakly positive, ++ = moderately positive, +++ = strongly positive.594 M Vakkala et al
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Negative control stainings were carried out by substituting non-
immune goat or rabbit serum for the primary antibodies. As a posi-
tive control for the immunostainings, a lymph node with follicular
hyperplasia was used.
The intensity of the immunostainings with all the antibodies was
evaluated by dividing the staining reaction in four groups:
1 = weak cytoplasmic staining intensity
2 = moderate cytoplasmic staining intensity
3 = strong cytoplasmic staining intensity
4 = very strong cytoplasmic staining intensity.
The quantity of the immunostaining was evaluated as follows:
0 = No positive immunostaining
1 = < 25% of tumor cells showing cytoplasmic positivity
2 = 25–50% of tumor cells showing cytoplasmic positivity
3 = 50–75% of tumor cells showing cytoplasmic positivity
4 = > 75% of tumor cells showing cytoplasmic positivity.
A combined score for the immunostaining, based on both quali-
tative and quantitative immunostaining, was composed by adding
both the qualitative and quantitative score which was then divided
into three groups:
+ = no or weak immunostaining; score 0–2
++ = moderate immunostaining; score 3–5
+++ = strong immunostaining; score 6–8.
For oestrogen and progesterone receptor staining, the slides were
rehydrated and then microwaved in EDTA buffer first for 3 min in
99°C and then for 27 min in 85°C. The endogenous peroxidase
was blocked with 0.1% hydrogen peroxide in absolute methanol
for 20 min. Non-specific staining was blocked by incubating the
slides in normal fetal calf serum for 20 min, followed by the
primary antibody and the avidin–biotin–peroxidase complex. The
slides were counterstained with methyl green, and the oestrogen
and progesterone receptor status was counted as previously
described (Helin et al, 1989).
3¢-end labelling of DNA in apoptotic cells
In order to detect apoptotic cells, in situ labelling of the 3¢-ends of the
DNA fragments generated by apoptosis-associated endonucleases
was performed using the ApopTag in situ apoptosis detection kit
(Oncor, Gaithersburg, MD, USA) as previously described
(Törmänen et al, 1995; Soini et al, 1996). The sections, after being
dewaxed in xylene and rehydrated in ethanol, were incubated with 20
mg ml–1 Proteinase K (Boehringer Mannheim GmbH, Mannheim,
Germany) at room temperature for 15 min. The endogenous peroxi-
dase activity was blocked by incubating the slides in 2% hydrogen
peroxide in PBS, pH 7.2. The slides were then treated with terminal
transferase enzyme and digoxigenin-labelled nucleotides after which
anti-digoxigenin–peroxidase solution was applied on the slides. The
colour was developed with diaminobenzidine after which the slides
were lightly counterstained with haematoxylin. For control purposes
we used tissue sections from hyperplastic lymph nodes showing an
increased number of apoptotic B-cells within germinal centres and a
low number of apoptotic T-cells in the interfollicular areas.
Assessment of the apoptotic index
Cells were defined as apototic if the whole nuclear area of the cell
labelled positively. Apoptotic bodies were defined as small posi-
tively labelled globular bodies in the cytoplasm of the tumour cells
which could be found either singly or in groups. To estimate the
apoptotic index (the percentage of apoptotic events in a given
area), apoptotic cells and bodies were counted in 10 high-power
fields (HPFs) and this figure was divided by the number of tumour
cells in the same HPFs.
In order to test the reproducibility of estimation of apoptosis by
the TUNEL method we also performed apoptosis assessment
by light microscopy in invasive breast carcinoma samples. The
assessment was based on the morphological criteria of apoptosis
described previously (Kerr et al, 1994). The morphological apop-
tosis was assessed from the same tumour samples and the estima-
tion of the apoptotic index was performed in a similar manner as
with the 3¢-end labelling method.
Statistical analysis
Comparisons between groups were made using the Mann–Whitney
U-test. The significance of associations was determined using
Fisher’s exact probability test and correlation analysis. Survival
was analysed by applying the Kaplan–Meier method with log-rank
analysis. Probability values ≤ 0.05 were considered significant.
Figure 1 Caspase immunostaining in non-neoplastic breast epithelial cells. Weak staining can be observed for caspase 3 (A) and caspase 8 (B) in the
epithelial cells
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RESULTS
Caspase 3, 6 and 8 expression in non-neoplastic
tissues
Diffuse, weak (+) and inconsistent cytoplasmic positivity was seen
for caspases 3, 6 and 8 in non-neoplastic ductal and lobular cells
(Figure 1). The immunoreactivity was slightly stronger in benign
epithelial lesions, like in areas with fibrocystic changes and it was
also pronounced in areas with inflammation. Curiously, ducts with
apocrine metaplasia frequently showed strong diffuse cytoplasmic
staining for caspases, especially caspase 8.
Caspase 3, 6 and 8 expression in breast preneoplastic
and neoplastic lesions
The results of the study are compiled in Table 1. Expression of
caspases 3, 6 and 8 in breast preneoplastic and neoplastic cells was
mainly diffuse, intracytoplasmic (Figures 2 and 3). Caspase 6 and
8, however, also expressed granular intracytoplasmic positivity the
amount of which, however, varied from tumour to tumour (Figure
4). This reaction pattern was especially prominent in invasive
carcinomas and many times gave an impression of being located in
the apoptotic bodies. Granular caspase 6 or 8 positivity did not,
however, associate with the apoptotic index (P = 0.19 and P = 0.98
respectively). In a few cases granular staining was also seen with
caspase 3. Interestingly, three carcinoma cases showed also
nuclear caspase 3 staining. Nuclear staining was not seen with
caspases 6 and 8. Caspase 8, on the other hand, sometimes
expressed membrane-associated staining.
There was an increase in the immunoreactivity of all three
caspases in parallel with the histological progression of the breast
lesion. Increased caspase 3 immunopositivity (++, +++), as
compared to benign ductal epithelium (+) was seen in 22% of
benign epithelial hyperplasias, 25% of atypical hyperplasias, 58%
of in situ carcinomas and 90% of invasive carcinomas. The corre-
sponding percentages for caspase 6 were 11%, 25%, 60% and
87%, and for caspase 8 were 22%, 57%, 84% and 83%. There was
a strong association between the expression of different caspases
in atypical hyperplasias and carcinomas. Concomitant strong
(+++), moderate (++), weak or negative (+) caspase 3 and 6
staining was seen in 79% of the cases (P ≤ 0.00001). The corre-
sponding percentages for caspase 3 and 8 and caspase 6 and 8 were
74% (P = 0.00057) and 71% (P = 0.01).
There were significantly more cases with increased (++, +++)
caspase 3 immunoreactivity in invasive breast carcinomas than in in
situ carcinomas (P = 0.00002), atypical hyperplasias (P = 0.00001)
or benign epithelial lesions (P = 0.00004). Also, in-situ carcinomas
had more cases with increased (++, +++) caspase 3 immunoreac-
tivity than atypical hyperplasias (P = 0.037) or benign epithelial
hyperplasias (P = 0.049). Similarly, invasive breast carcinomas had
more cases showing increased (++, +++) caspase 6 positivity than
in-situ carcinomas (P = 0.00024), atypical hyperplasias (P =
0.00002) or benign epithelial hyperplasias (P= 0.00001), and in-situ
carcinomas showed more cases with increased caspase 6 immunore-
activity (++, +++) than atypical hyperplasias (P = 0.025) or benign
epithelial hyperplasias (P = 0.00657). With caspase 8, however,
invasive breast carcinomas did not show significantly more cases
with increased (++, +++) positivity than in-situ carcinomas (P =
0.57) or atypical hyperplasias (P = 0.99), but there were more cases
than in benign epithelial hyperplasias (P = 0.00035). Also, in-situ
carcinomas did not have significantly more cases with increased
(++, +++) caspase 8 positivity than atypical hyperplasias (P = 0.99),
but the difference with benign epithelial hyperplasias was signifi-
cant (P = 0.00032). Invasive breast carcinomas, however, showed
significantly more cases with strong (+++) caspase 8 positivity than
in-situ carcinomas (P = 0.02) or atypical hyperplasias (P = 0.0008),
and in-situ carcinomas showed significantly more cases with strong
A
B
Figure 2 Caspase staining in in situ carcinomas. Strong intracytoplasmic
staining for caspase 3 (A) and caspase 6 (B) can be seen in ductal in-situ
breast carcinoma and for caspase 8 (C) in lobular in-situ carcinoma
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(+++) caspase 8-positive cases than atypical hyperplasias (P= 0.02).
Similar associations were found with caspase 3 and 6 (P < 0.00001,
P = 0.00008, P = 0.057 for caspase 3 respectively, and P = 0.006, P
= 0.00002 and P = 0.12 for caspase 6 respectively).
Low- and intermediate-grade in-situ lesions of the breast had
significantly fewer cases with strong (+++) caspase 3, 6 and 8
immunoreactivity than high-grade lesions (P = 0.0045, P = 0.049,
P = 0.0001 respectively). In invasive carcinomas, however, a
similar association between strong (+++) caspase immunoreac-
tivity and high-grade tumours was not found (P = 0.27, P = 0.26
and P = 0.69 respectively).
Apoptotic index in invasive and in-situ carcinomas and
in atypical and benign epithelial hyperplasias
The apoptotic index in benign epithelial hyperplasias, atypical
hyperplasias, in situ carcinomas and invasive carcinomas are
shown in Table 1. There was a significantly lower apoptotic index
in benign and atypical hyperplasias compared to in situ or invasive
carcinomas (P < 0.001). Invasive carcinomas displayed a higher
apoptotic index than atypical (P < 0.012) or benign epithelial
hyperplasias (P < 0.001). Also, in situ carcinomas had a higher
apoptotic index than atypical (P = 0.004) or benign epithelial
hyperplasias (P < 0.001). No difference was, however, observed in
the apoptotic index between atypical and benign epithelial hyper-
plasias (P = 0.97).
Low-grade in situ lesions showed a significantly lower extent of
apoptosis (0.23 ± 0.20%) than intermediate- and high-grade
lesions (1.05 ± 1.15%) (P < 0.001). Similarly, low- and inter-
mediate-grade lesions showed a significantly lower extent of
apoptosis (0.51 ± 0.73%) than high-grade lesions (1.04 ± 1.25%)
(P = 0.012). In situ lobular carcinomas showed a significantly
lower extent of apoptosis than comedo-type lesions (P < 0.001).
The apoptotic index in grade I invasive tumours was lower
(0.75 ± 0.71%) than in grade II (0.95 ± 1.55%) or grade III
(1.10 ± 1.10%) lesions and lobular invasive carcinomas had a
lower apoptotic index (0.54 ± 0.60%) than ductal carcinomas
(1.00 ± 1.26%). There was, however, no significant difference
A B
Figure 3 Caspase staining in breast invasive carcinomas. Strong staining for caspase 3 can be seen in invasive ductal (A) and for caspase 6 in invasive
lobular (B) carcinoma
Figure 4 Granular caspase 6 staining in invasive breast carcinoma. The black dots in the figure correspond to positively stained fragments which are
reminiscent of apoptotic cells and bodies (A). In this figure caspase 6 immunostaining in a lymphatic follicle from the control lymph node is shown. Apoptotic
cells and fragments show a similar positivity as shown in the breast carcinoma (B)
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between invasive grade I and grade II–III or grade I–II and grade
III tumours (P = 0.42 and P = 0.22 respectively) or between inva-
sive ductal or lobular carcinomas (P = 0.97).
Association of caspases 3, 6 and 8 with apoptosis,
oestrogen and progesterone receptor status and
survival
In all cases, strong (+++) caspase 3 positivity was significantly
associated with increased apoptosis (1.00 ± 1.27% for strong
expression, 0.36 ± 0.56% for other cases, P = 0.007). A similar
association was seen with caspase 6 (1.11 ± 1.21% vs 0.62 ±
0.99%, P = 0.012) and caspase 8 (1.06 ± 1.24% vs 0.53 ± 0.90%,
P = 0.009). There was no significant association between strong
(+++) caspase 3, 6 or 8 immunoreactivity and a positive oestrogen
or progesterone receptor status in invasive carcinomas (P = 0.29,
P = 0.53, P = 0.54; and P = 0.33, P = 0.45 and P = 0.08 respec-
tively). In invasive carcinomas, no association with patient survival
was observed with caspase 3, 6 or 8 (P = 0.77, P = 0.94 and
P = 0.14 respectively).
Comparison of the TUNEL method with light
microscopy
To study the reproducibility of the TUNEL method, we also evalu-
ated the apoptotic index by morphological criteria in invasive breast
carcinomas and compared the values with those obtained by
TUNEL. The average apoptotic index in invasive carcinomas was
0.82 ± 0.97%. According to the results, there was a strong positive
correlation between the extent of apoptosis obtained by TUNEL and
light microscopic morphology (r = 0.5018, P < 0.001).
DISCUSSION
This study was undertaken to investigate the expression of
caspases 3, 6 and 8 in benign and atypical hyperplasias, and in situ
and invasive carcinomas of the breast. Also, the extent of apop-
tosis was studied and the results were correlated with the expres-
sion of the caspases in the lesions.
According to the results there was a gradual increase in the expres-
sion of caspases 3, 6 and 8 along with the progression of the breast
lesion. Moreover, the expression of all these caspases was strongly
associated with the rise in the apoptotic index. The results thus indi-
cate increased synthetic activity of these proteins during neoplastic
progression of breast epithelial cells. Immunohistochemistry,
however, cannot discriminate between the active and inactive forms
of the caspases, and only the active form is responsible for the effects
of the caspases leading to apoptosis. AIF may, however, up-regulate
the synthesis of caspases prior to activating them. Topoisomerase II
inhibitor etoposide, for instance, up-regulates caspases 2 and 3 in
neoplastic leukaemic cell lines prior to induction of apoptosis, and
up-regulation of caspase 2 mRNA has been shown in response to
ischaemia-induced cell death (Harvey et al, 1997; Droin et al, 1998).
In our recent study, caspase 3, 6 and 8 immunoreactivity was
found in 70–80% of pancreatic adenocarcinomas (Virkajärvi et al,
1998). In lymphomas caspase 3 expression was increased in the
large cell population of large- and mixed-cell follicular non-
Hodgkin’s lymphomas and in Reed–Sternberg cells of Hodgkin’s
disease (Chhanabhai et al, 1997; Krajewski et al, 1997). There
may, however, be differences in the expression of caspases in
histologically different tumours and tumours of different sites. In
cell line studies, the expression of caspase mRNA has been shown
to be heterogeneous (Droin et al, 1998). Interestingly, caspase 3 is
able to modulate the function of bcl-2 by cleaving it to a shorter,
truncated form which, in contrast to the longer anti-apoptotic
form, is pro-apoptotic (Fujita and Tsuruo, 1998). Also, bcl-xL,
another anti-apoptotic protein, is cleaved by caspases to a similar
truncated pro-apoptotic fragment (Clem et al, 1998).
The immunostaining with all three caspase antibodies was cyto-
plasmic and mainly diffuse. This is in line with their known cyto-
plasmic location. Caspases 6 and 8 also showed granular or
fragmented cytoplasmic staining. Such staining was only rarely
observed with caspase 3. The granular or fragmented cytoplasmic
staining many times appeared to result from staining of the frag-
ments suggesting that the concentration of caspases 6 and 8 would
be higher in them. The quantity of the granular staining of these
two caspases did not, however, associate with the apoptotic index
of breast tumours. This might be due to their heterogenous expres-
sion in apoptotic fragments in different tumours, i.e. not all
tumours showed staining of apoptotic fragments for caspase 6 to 8
to a similar degree.
In addition to cytoplasmic staining, caspase 8 sometimes also
expressed membrane-bound staining. Such staining might be asso-
ciated with FLICE, the proform of caspase 8, and thus indirectly
might reflect a high concentration of the APO-1/FAS receptor
complex on the cell membrane and a consequent formation of
DISC on tumour cells in some cases. Also nuclear staining was
seen, but only with caspase 3. Nuclear caspase 3 staining has
previously been described in some non-neoplastic tissues such as
type II pneumocytes of the lung, or epithelial cells of the colon or
stomach (Krajewska et al, 1997). In non-neoplastic breast epithe-
lial cells, no nuclear staining was, however, observed. We also
found a strong association between the expression of all three
caspases. This might suggest a mutual regulation of their synthesis
in neoplastic breast epithelial cells.
Analysis of the apoptotic index in the breast lesions showed a
progressive increase in apoptosis in parallel with the biological
aggressiveness of the lesion. The results further show that in in situ
lesions, there are differences in the apoptotic index depending on
the histology or grade of the lesions. Not surprisingly, in situ
comedo-type of lesions showed the highest extent of apoptosis
followed by solid, cribriform and papillary variants. The lowest
apoptotic index was seen in lobular in situ carcinoma. Similarly,
high-grade in situ lesions showed a higher extent of apoptosis than
intermediate- or low-grade lesions. The results thus suggest that
genes that are activated in high-grade lesions may also be respon-
sible for the induction of a higher extent of apoptosis in them. The
expression of some cancer genes, such as p53 and c-erbB2, has
been shown to be different in high-grade in situ lesions compared
to low- or intermediate-grade lesions (van de Vijver et al, 1988;
O’Malley et al, 1994; Mack et al, 1997). Moreover, comedo-type
of in situ carcinomas display less receptor positivity than other in
situ carcinomas (Bur et al, 1992; Barnes and Masood, 1990).
Oestrogenic stimulation has been shown to inhibit apoptosis
through up-regulation of bcl-2 mRNA, and a lack of oestrogen
receptors might thus lead to an increased apoptosis in high-grade
in situ lesions (Wang and Phang, 1995). In line with this, bcl-2
immunohistochemistry was shown to be reduced in poorly differ-
entiated in situ carcinomas (Mustonen et al, 1997). Furthermore,
there is also an inverse association between the apoptotic index
and a positive oestrogen or progesterone receptor status and posi-
tive bcl-2 immunohistochemistry in invasive breast carcinomas(Lipponen et al, 1994; Mustonen et al, 1997). However, we did not
observe any association between the expression of caspases and
the oestrogen and progesterone receptor status suggesting that
their synthesis is not influenced by stimulation of these receptors.
There are several factors which may hamper the use and evalua-
tion of the results obtained by the TUNEL method (reviewed in
Soini et al, 1998). Because of this we compared the results with
light microscopic morphology and found a statistically significant
correlation between both methods. Even though there was a
statistically significant correlation, some labelling in the TUNEL
method may also be due to DNA fragmentation not necessarily
associated with apoptosis.
In conclusion, our results show that the expression of caspases
3, 6 and 8 is increased in parallel with the neoplastic progression
of the breast lesions. Their abundant expression in pre-carcinoma-
tous and carcinomatous breast lesions suggests an important role
in the execution of apoptosis in malignant breast disease. In accor-
dance with this, their expression was significantly associated with
the overall apoptotic index of the lesions.
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